

August 17, 2020

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Atsushi Udoh, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Marketing Approvals for
2 Ingredients / 7 Products of Generic Drugs for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has received approvals for marketing of 2 ingredients / 7 products of generic drugs today on August 17, 2020 as below.

Products list approved for marketing

Classes	Product Name	Original Brand Name
Agents for pain treatment (neuropathic pain, fibromyalgia)	Pregabalin OD Tablets 25mg/75mg/150mg “KMP”	LYRICA OD Tablets 25mg/75mg/150mg
Therapeutic agent for Alzheimer dementia	Rivastigmine Tape 4.5mg/9mg/13.5mg/18mg “KMP”	Exelon Patch 4.5mg/9mg/13.5mg/18mg RIVASTACH Patches 4.5mg/9mg/13.5mg/18mg